A spokesperson confirmed the Danish drugmaker has asked U.S. regulators to clear an oral version of its weight loss drug ...

Novo Nordisk remains an industry leader, and currently offers both a 2.7% dividend yield and compelling value that can work ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

Novo Nordisk (NYSE:NVO) stock has experienced a significant decline, dropping 35% from over $90 in early March to around $58 ...

Now some doctors are trying GLP-1 drugs — popular medications for weight-loss and Type 2 diabetes — as part of lymphedema ...

Brazil is among the five largest markets for Novo Nordisk, the Danish drugmaker said. It also exports to more than 70 countries out of Brazil. With the investment, the production capacity will have "a ...

chief scientific advisor at Novo Nordisk. “It feels wonderful to be recognized, not just for me personally, but for all my co-workers and trainees throughout my career,” Drucker said. “For a physician ...

Brazil is among the five largest markets for Novo Nordisk, the Danish drugmaker said. It also exports to more than 70 countries out of Brazil. With the investment, the production capacity will ...

Bangkok, April 2025 – Chulalongkorn University, in collaboration with Novo Nordisk Pharma (Thailand ... through digital engagement. With more than 40% of Thai individuals currently classified ...

Novo Holdings, the controlling shareholder of weight loss drugmaker Novo Nordisk A/S (NYSE ... and Wegovy sales more than doubled to 19.87 billion Danish kroner. Don’t Miss: Deloitte's fastest ...

If you are looking for an AI stock that is as promising as NVIDIA but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock. We covered Novo Nordisk A/S ...

As Novo Nordisk A/S shares head for their worst month in more than two decades, the days when the Danish drugmaker was valued at more than $600 billion are becoming a distant memory. Investors ...